Potential of Gene Editing – Part 1 of Interview with Prof Waseem Qasim
My highlight of the 2015 annual meeting of the American Society of Hematology (ASH) was interviewing Professor Waseem Qasim, who is a Consultant in Paediatric Immunology and Bone Marrow Transplantation at Great Ormond Street Hospital (GOSH) and Professor of Cell & Gene Therapy at the Institute of Child Health, which is part of University College London (UCL).
In a poster presented at ASH 2015, Prof Qasim together with colleagues from GOSH & UCL reported the “first in man” use of a gene edited, off-the-shelf, allogeneic CAR T cell from Cellectis, a company we have written extensively about on the blog. It was probably one of the leading posters at the meeting, at least in terms of the amount of interest it generated, and the crowds I saw reading it.
There was far too much content in the interview for one blog post, so we’ve split into two, with Part 1 focusing on gene editing and Part 2 discussing in detail the case reported in the poster.
Subscribers can login to read more or you can purchase access.
This content is restricted to subscribers
